VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.
Company profile
Website
CEO
Jeffrey R. Baxter
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Paulson Capital , Paulson Capital Corp
SEC CIK
Corporate docs
IRS number
930589534
Latest filings (excl ownership)
15-12G
Securities registration termination
16 May 16
EFFECT
Notice of effectiveness
11 May 16
EFFECT
Notice of effectiveness
11 May 16
8-K
SciVac Therapeutics and VBI Vaccines Announce Completion of Merger Transaction
9 May 16
8-K
Entry into a Material Definitive Agreement
9 May 16
POS AM
Prospectus update (post-effective amendment)
9 May 16
POS AM
Prospectus update (post-effective amendment)
9 May 16
S-8 POS
Registration of securities for employees (post-effective amendment)
9 May 16
S-8 POS
Registration of securities for employees (post-effective amendment)
9 May 16
S-8 POS
Registration of securities for employees (post-effective amendment)
9 May 16
Latest ownership filings
SC 13D/A
ARCH VENTURE FUND VI LP
25 Jul 23
SC 13D/A
ARCH VENTURE FUND VI LP
6 May 20
SC 13G/A
Vbi Vaccines Inc.
12 Feb 20
4
STEVEN GILLIS
23 Sep 19
SC 13G/A
Vbi Vaccines Inc.
11 Feb 19
SC 13G
Vbi Vaccines Inc.
29 May 18
SC 13D/A
Vbi Vaccines Inc.
9 Feb 18
3
Jeff Baxter
19 Apr 17
3
Michel DeWilde
19 Apr 17
4
Michel DeWilde
19 Apr 17
Institutional ownership, Q2 2024
6.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 44 |
Opened positions | 34 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 1.75 bn |
Total shares | 17.87 mm |
Total puts | 0.00 |
Total calls | 823.20 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Arch Venture Fund Vi | 13.03 mm | $15.96 mm |
Brii Biosciences | 2.13 mm | $3.11 mm |
Perceptive Advisors | 1.26 mm | $832.73 mm |
Alyeska Investment | 608.60 k | $401.68 mm |
Vanguard | 184.44 k | $121.73 mm |
Geode Capital Management | 178.82 k | $118.05 mm |
BLK BlackRock | 108.59 k | $71.67 mm |
Cambridge Investment Research Advisors | 67.11 k | $44.00 k |
STT State Street | 43.89 k | $28.97 mm |
NTRS Northern Trust | 32.92 k | $21.73 mm |